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Abstract Aniridia is a rare, bilateral, congenital ocular disor-
der causing incomplete formation of the iris, usually charac-
terized by iris aplasia/hypoplasia. It can also appear with other
ocular anomalies, such as cataracts, glaucoma, corneal pannus,
optic nerve hypoplasia, macular hypoplasia, or ectopia lentis.
In the majority of cases, it is caused by mutation in the PAX6
gene, but it can also be caused by microdeletions that involve
the 11p13 region. Twelve unrelated patients of Polish origin
with a clinical diagnosis of aniridia were screened for the
presence of microdeletions in the 11p13 region by means of
multiplex ligation probe amplification (MLPA). Additionally,
the coding regions of the PAX6 gene were sequenced in all
probands. MLPA examination revealed different size deletions
of the 11p13 region in five patients. In three cases, deletions
encompassed the entire PAX6 gene and a few adjacent genes.
In one case, a fragment of the PAX6 gene was deleted only. In
the final case, the deletion did not include any PAX6 sequence.
Our molecular findings provide further evidence of the exis-
tence of the distant 3′ regulatory elements in the downstream
region of the PAX6 gene, which is known from other studies to
influence the level of protein expression. Sequence analysis of
the PAX6 gene revealed the three different point mutations in
the remaining four patients with aniridia. All the detected
mutations were reported earlier. Based on accomplished
results, the great diversity of the molecular basis of aniridia
was found. It varies from point mutations to different size
deletions in the 11p13 region which encompass partly or
completely the PAX6 gene or cause a position effect.
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Introduction
Aniridia (MIM:106210) is a rare, bilateral, congenital
ocular disorder causing incomplete formation of the iris.
The visual impairment caused by iris aplasia/hypoplasia
might be enhanced by several ocular anomalies, such as
cataracts, glaucoma, corneal pannus, macular hypoplasia,
nystagmus, and photophobia. The prevalence of aniridia in
the general population is approximately 1 in 64,000 to 1 in
96,000 live births. Two-thirds of cases are familial, with
autosomal dominant mode of inheritance, complete pene-
trance, and variable expressivity. One-third of cases are spo-
radic and result from de novo mutations (Kokotas and
Petersen 2010).
Mutations in the PAX6 gene
PAX6 (MIM:607108; NM_001604.4) was identified as a
candidate gene for aniridia by positional cloning in 1991
(Ton et al. 1991). Mutations in the PAX6 gene are the major
cause of congenital aniridia. PAX6 is a member of the paired
box gene family, located on chromosome 11p13, and con-
sists of 14 exons that span over 22 kb in length. It encodes a
422-amino acid transcriptional factor, involved in oculogen-
esis and other developmental processes. The protein con-
tains three functional domains: paired domain (PD) and
homeodomain (HD), separated by the proline/serine/threo-
nine-rich transactivation domain (PST). The paired domain
comprises two structurally distinct DNA-binding subdomains:
the N-terminal subdomain (NTS) and the C-terminal subdo-
main (CTS) (Kokotas and Petersen 2010). The protein is
abundantly expressed in the forebrain, early eye structures,
ventral spinal cord, and endocrine pancreas (Lauderdale et al.
2000). Pathogenic alterations in the PAX6 gene reported to
date include: nonsense, splicing, frame-shifting insertions or
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deletions, in-frame insertions or deletions, missense, and run-on
mutations (D’Elia et al. 2007). Human PAX6 mutations are
archived in the PAX6 Allelic Variant Database (LOVD:
Leiden Open Variation Database, http://lsdb.hgu.mrc.ac.uk/
home.php). The majority of mutations in the PAX6 gene are
nonsense mutations, which are considered to produce truncated
transcripts that activate the nonsense-mediated decay
(NMD) process, resulting in haploinsufficiency of PAX6
(Fantes et al. 1995).
11p13 deletions
Aniridia can be also caused by chromosomal rearrangements
that involve the 11p13 region. A significant proportion of
chromosomal rearrangements are submicroscopic microdele-
tions (Crolla and van Heyningen 2002). There have been
described cases of aniridia with deletions not involving the
structure of the gene but with the removal of 3’ regulatory
elements essential for adequate PAX6 expression and known
as a “position effect” (Fantes et al. 1995).
Chromosomal alterations in the chromosome 11p, encom-
passing the PAX6 and WT1 (*607102) genes, may cause
WAGR syndrome (MIM:194072). WAGR syndrome is a rare
contiguous gene deletion syndrome, clinically associated with
Wilms’ tumor, aniridia, genitourinary anomalies, and mental
retardation (Fischbach et al. 2005). Wilms’ tumor is one of the
most common solid tumors of childhood, which affects ap-
proximately 1 in 10,000 children. In patients with WAGR
syndrome, the risk that Wilms’ tumor will develop reaches
45 % (Crolla and van Heyningen 2002).
The aim of this study was to analyze the genetic back-
ground of disease in Polish patients with aniridia.
Materials and methods
Patients
This study comprises 12 unrelated patients of Polish origin,
with a clinical diagnosis of aniridia, based on ophthalmo-
logic examination and family history. Among them, there
are five patients with positive family history, six sporadic
cases, and one patient (p6) who was adopted, for whom we
have no information about the patient’s biological parents.
The ophthalmologic findings of the patients are summarized
and compared in Table 1. The local ethics committee ap-
proved the study and a written informed consent was
obtained from all subjects or their legal guardians.
Methods
Genomic DNA was extracted from venous blood samples
using a standard salting-out procedure. Patients were screened
for structural rearrangements in the 11p13 region, using mul-
tiplex ligation probe amplification (MLPA) analysis. MLPA
allowed in the first instance to exclude WT1 gene deletion,
associated with a high risk of Wilms’ tumor. MLPA reaction
was performed using the P219-B1 commercial kit (MRC-
Holland, Amsterdam, Netherlands), following the manufac-
turer’s instructions and using an exactly defined amount of
genomic DNA (200 ng). The kit contains probes for the PAX6
gene (with the exception of exon 6) and for the following
genes located upstream, WT1, HIPK3, LMO2, EHF, CD44,
and RCN1, and downstream, BDNF, FSHB, DCDC1, and
ELP4, of PAX6. Data were intra-normalized by dividing the
area of the peak for each amplification product by the total
area of the reference probes’ products in the probemix. Inter-
sample normalization was achieved by dividing the intra-
normalized probe ratio of all reference samples. Data normal-
ization was performed within one experiment (MRC-
Holland). Peak areas in the range 0.65–1.31 were considered
normal, below 0.65 as a deletion, and above 1.31 as a dupli-
cation. Each MLPA analysis included several control samples
(DNA from healthy individuals).
The coding regions of the PAX6 gene were sequenced
(exon 5a included) to exclude point mutations. PCR prod-
ucts were separated on an ABI 3130xl Capillary Sequencer
(Applied Biosystems). Additionally, in patients p2, p3, and
p6, the PAX6 gene promoter was sequenced. The sequenced
fragment included 5′UTR and 1,500 nucleotides upstream
of the 5′UTR fragment of the PAX6 gene. The sequences of
the primers used in the amplification and sequencing of
the PAX6 gene and PAX6 promoter are given in Table 2.
Subsequently, to uncover probable, smaller, rare copy num-
ber variations (CNVs), array comparative genomic hybrid-
ization analysis (using NimbleGen Human CGH 6x630K,
Roche) of these three patients was performed. The DNA
labeling reaction and hybridization were carried out accord-
ing to the manufacturer’s instructions.
Results
MLPA examination revealed different size heterozygous
deletions of the 11p13 region in five patients. In three cases,
deletions encompassed the PAX6 gene and a few adjacent
genes. The heterozygous deletion in patient p8 contains five
annotated genes: PAX6, doublecortin domain-containing
protein 1 (DCDC1, MIM:608062), elongation factor protein
4 (ELP4, MIM:606985), brain-derived neurotrophic factor
(BDNF, MIM:113505), and beta polypeptide of follicle-
stimulating hormone (FSHB, MIM:136530) (Fig. 1a). The
heterozygous deletion in patient p9 harbors the following
six genes: PAX6, DCDC1, ELP4, FSHB, reticulocalbin 1
(RCN1, MIM:602735), and DKFZp686K1684. In patient
p11, a large heterozygous deletion of the 11p13 region
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(WT1 gene included) was found (Fig. 1b), which confirmed
the diagnosis of WAGR syndrome. In one patient (p12), a
heterozygous deletion of several contiguous exons (exons
1–8) of the PAX6 gene was found (Fig.1c). In patient p10,
MLPA revealed a heterozygous deletion of approximately
0.6 Mb on chromosome 11. The deletion did not include the
PAX6 sequence. The following four genes located
downstream of PAX6 are present in the deleted region:
DCDC1, zinc finger CLS domain containing protein 3
(DPH4, MIM:611072), IMP1 inner mitochondrial mem-
brane peptidase (IMMP1L, MIM:612323), and ELP4 (pub-
lished data, Wawrocka et al. 2012).
The analysis of the coding region of the PAX6 gene by
direct sequencing revealed three different point mutations in
Table 2 Primers used for the amplification and sequencing of the PAX6 gene and PAX6 gene promoter
PAX6 gene
Exon Sense primer Antisense primer Product size (bp)
4 AACAGAGCCCCATATTCGAG GAGTCCCTGTGTCCTCCCC 143
5 CTCTTCTTCCTCACTCTGC GAAATGAAGAGAGGGCGTTG 268
5a CTCTACAGTAAGTTCTCATACC GGAAGTGGACAGAAAACCAC 197
6–7 TTTGATGCATCTTCAGGCAG GACTCCCCACACTTGACTCC 748
8 TGGGTGACTGTGTCTTCAGG AATGGTTGGGAGAGTAGGGG 300
9 TTAAGACTACACCAGGCCCC TGAAGATGTGGCATTTACTTTG 294
10–11 TTGATGCACAGTTTGGTCAAC GTGAGAGTCAGAGCCCGGAG 602
12 TAAACCTGTTTGCTCCGGG AAGCTCTCAAGGGTGCAGAC 282
13 CTTGTTGGCAGAGTTCCTCG AGGAGTTAAACACGCCCTCC 347
14 CCATGTCTGTTTCTCAAAGGG AAGCTCAACTGTTGTGTCCC 222
PAX6 gene promoter
product 1 AAGAGTCTAGCGTACCCTTCG CTGACCACACACCAGAAGTC 288
product 2 TGGACTTCTGGTGTGTGGTC GGTATGTCAGCGTGTGTCGT 185
product 3 CACGCTGACATACCGACATC AAGCCAGGGGAGATAAGAGG 156
product 4 AGAGAATCCCTCCCAGCATT TCCTCACCAAACACTCACCA 163
product 5 CAGCCGCACTTAGTCAACAA CGCCCTTTCTTCTCTCCTTT 195
product 6 GCTTCCGAAAGGAGAAAGGA CCCCTTGGAAGAAGAGGAAA 216
product 7 CCCCTTTCCTCTTCTTCCAA CAATTGGTCCGTTTGTTTGA 386
product 8 ACCCAGAAACCTTCACTTGAC AGCAAAACACTTCCTCCTGC 416





Nystagmus Photophobia Other features
p1 + + + + + −
p2 + + − − − Complex microphthalmia, lens subluxation
p3 + − + − − Atrophy of the eyeballs, blindness
p4 + + − + + Atrophy of the optic nerves, persistent hyaloid artery
p5 + (partial) + − + + Atrophy of the optic nerves, psychomotor
developmental delay
p6 + − − + + Facial dysmorphy, left kidney agenesis
p7 + + − + − −
p8 + − − + − Astigmatism
p9 + + − + + −
p10 + (partial) + − − − Lens subluxation, macular hypoplasia
p11 + − − + − Psychomotor developmental delay, muscular hypotony,
cryptorchidism (WAGR syndrome)
p12 + + + + + Atrophy of the eyeballs, uveal coloboma























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 The normalized multiplex ligation probe amplification (MLPA) results of the three probands. A patient p8, B patient p11,C patient p12. The light
gray columns represent the deleted probes
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the remaining four patients. All the detected mutations were
previously reported. In patient p1, we identified a c.718C>T
heterozygous nonsense mutation, which occurred in the
protein homeodomain (HD), resulting in a change of arginine
to stop codon (p.Arg240*). In patients p4 and p7, another
heterozygous nonsense mutation at position c.949C>T was
identified. It is present in the PST domain coding region, and
results in a premature termination of the PAX6 protein
(p.Arg317*). According to the database, the identified muta-
tions are common deleterious mutations in the PAX6 gene and
they probably encode a non-functional protein. Bidirectional
sequencing of exon/intron boundaries for patient p5 resulted
in the identification of a nucleotide substitution at the splice
donor sequence of intron 6, c.357+1G > A (IVS6+1G > A)
(Fig. 2).
Sequencing of the PAX6 gene promoter in patients p2, p3,
and p6 did not identify any mutation in this region. So, the
molecular methods used in this study did not allow to detect
any mutations in patients p2, p3, and p6. Therefore, array
comparative genomic hybridization analysis of these three
patients was performed. However, array comparative ge-
nomic hybridization (aCGH) analysis also did not reveal
any causative mutation. The patients’ molecular findings
are summarized in Table 3.
Discussion
This is the first molecular study carried out on Polish patients
with aniridia. In this study, we identified the alterations that
cause the disease in 9 of 12 examined (75 %) patients with
aniridia. The major finding of the present study is the great
diversity of the molecular basis of aniridia in Polish patients. It
is also worth mentioning that, in our group of patients, aniridia
is more frequently caused by large deletions than by the PAX6
gene point mutations. This statement is in contrast to larger
studies done by Ton et al. (1991), Kokotas and Petersen
(2010), and Park et al. (2012). Those researchers stated that
heterozygous mutations in the PAX6 gene are found in about
40–80 % of all non-syndromic aniridia patients. However, we
must remember that our results are based on a small group,
thus, our conclusion requires further verification with a larger
cohort of aniridia patients.
The large deletion containing not only PAX6 but also
several other genes and the RCN1 gene was detected by
MLPA analysis in patient p9 (Table 3). The RCN1 gene is a
Ca2+ binding protein, participating in the secretory pathway.
Favor et al. (2009) reported that mouse, containing a het-
erozygous deletion of the AX6 and RCN1 genes, presents an
extreme microphthalmia. They suggest that RCN1 may have
an influence on the eye phenotype in PAX6 contiguous gene
deletions. A familial case of aniridia resulting from a dele-
tion containing PAX6, RCN1, and DKFZp686k1684 was
reported by Zhang et al. (2011). Severe visual impairment
observed in the described family is compatible with the
mouse phenotype reported by Favor et al. (2009). Patient
p9 contains a very similar deletion of the downstream flank-
ing region of PAX6 to the family described by Zhang et al.
(2011). However, our patient exhibits no significant pheno-
type differences in comparison to other aniridia patients
presented in this study. Microphthalmia was not observed.
When the deletion does not include the PAX6 sequence,
then the so-called “position effect” is the underlying patho-
genic mechanism of aniridia in these patients. Such a case is
observed in patient p10, who has been diagnosed to have
aniridia, despite the fact that the structure of the PAX6 gene
was normal. Submicroscopic deletions not involving the PAX6
gene in the patients with aniridia were previously described by
several authors (Lauderdale et al. 2000; D’Elia et al. 2007;
Davis et al. 2008; Wawrocka et al. 2012). MLPA analysis
revealed in this patient a heterozygous deletion encompassing
several genes, including the ELP4 gene. Kleinjan et al. (2006)
confirmed that cis-regulatory elements located within the
introns of the ELP4 gene are PAX6-specific long-range control
elements, essential for normal expression of the gene.
Functional studies in human cells and animal models con-
firmed the presence of 3′ regulatory elements in the down-
stream region of PAX6, which are essential for normal expres-
sion of the gene. Our molecular findings provide further
evidence of the existence of the distant 3′ regulatory elements
in the downstream region of the PAX6 gene, which are known
from other studies to influence the level of protein expression.
DNA sequencing of the PAX6 gene revealed three different
mutations: two nonsense mutations, c.718C>T and c.949C>
T (in two patients), and one splice-site mutation, c.357+1G>
A. It was previously described that the mutation c.357+1G>
A lead to the use of a cryptic splice donor site within exon 6,
leading to an in-frame deletion of 36 amino acids from the PD
(Hingorani et al. 2009). The heterozygous mutation c.718C>
T (p.Arg240*) in patient p1 occurred in the protein HD. In two
unrelated patients (p4 and p7), identical heterozygous substi-
tution c.949C>T (p.Arg317*) in the PST domain coding
region was discovered. In accordance to the PAX6 mutation
Fig. 2 Forward sequence analysis of exon 6 and adjacent intronic
sequence of the PAX6 gene in patient p5. The arrow indicates the
heterozygous G/A transition in intron 6 at position +1 c.357+1G > A
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database: c.718C>T and c.949 C>T are the most frequent
PAX6 mutations causing aniridia. Despite the presence of the
same mutation, both patients represent quite divergent pheno-
types. Singh et al. (1998) showed that the variable phenotype
could be explained by differences in PAX6 protein levels, the
ratio of mutant and normal protein, and interaction with dif-
ferent molecular factors. It was reported that mutations behind
the HD could lead to more severe phenotypes in comparison
with truncating mutations in the PD or HD domains (Kokotas
and Petersen 2010; Park et al. 2012). This partly agrees with
our observations that patient p4 (mutation in the PST domain)
showed a more severe phenotype of aniridia in comparison to
patient p1 (mutation in the HD) (Table 1).
We have not determined any genetic causes of aniridia in
three patients (p2, p3, and p6). The disease can be caused by
abnormalities in the PAX6 gene promoter or in the regula-
tory elements that affect the normal expression of the gene
but are not routinely subjected to sequencing. Therefore, we
decided to sequence the PAX6 gene promoter in these
patients. However, the sequencing did not reveal any muta-
tion in the PAX6 promoter. Another possible explanation for
this fact is that chromosomal rearrangements that involved a
gene or genes in the 11p13 region do not include the probes
used in the MLPA analyses. Patient p2 suffers from aniridia
and microphthalmia. The presence of microphthalmia with
aniridia suggests the possibility of genocopy. Therefore,
another gene involved in oculogenesis can be responsible
for the disease. Possibly, the damage of the iris only resem-
bles aniridia. aCGH analysis of patient p2 was performed, as
well as in two other patients, in whom the genetic background
of aniridia was not determined (p3, p6). This analysis allows
to uncover smaller, rare CNVs that cannot be detected by
lower resolution molecular techniques. However, no causative
mutation was found.
Ophthalmic findings revealed nearly no phenotypic var-
iabilities of the aniridia. Patients having deletion 3′ to the
PAX6 gene exhibit no significant phenotypic differences
compared to the patients with point mutations in the PAX6
gene. Due to quite the homogenous clinical symptoms and a
small number of patients, we were not able to define any
genotype–phenotype correlations. The findings of the current
study are consistent with those of D’Elia et al. (2007), Lim et al.
(2012), and Park et al. (2012), who did not find any phenotypic
differences according to the identified genotype. Defining the
genotype–phenotype correlation requires the analysis of a larg-
er cohort of patients.
In connection to the great variability of mutations in anir-
idia patients, it is recommended to perform several analyses to
detect the genetic background of aniridia. First of all, we care
about the exclusion of life-threatening Wilms’ tumor (associ-
ated with the WT1 gene deletion) and then the detection of
genetic causes of aniridia. Therefore, we decided to perform
MLPA analysis first (to detect structural rearrangements in the
PAX6 gene and 11p13 region) and then PAX6 gene sequencing
(to identify point mutations). Additionally, gene sequencing is
not usually used to detect copy number changes; therefore, in
our opinion, it is better to begin the molecular analysis with
MLPA or aCGH.
Table 3 Molecular analysis
results
F familial, S sporadic, N normal
sequence





p1 F N c.718C>T –
p2 F N N N
p3 S N N N
p4 S N c.949C>T –
p5 S N c.357+1G>A –
p6 No data N N N
p7 F N c.949C>T –
p8 S Heterozygous deletion: PAX6, DCDC1, ELP4,
BDNF, FSHB
N –
p9 S Heterozygous deletion: PAX6, DCDC1, ELP4,
FSHB, RCN1, DKFZp686k1684
N –
p10 F Heterozygous deletion: DCDC1, DPH4,
IMMP1L, ELP4
N –
p11 S Heterozygous deletion of the 11p13 region
(including WT1)
N –
p12 F Heterozygous deletion: exons 1–8 of PAX6 N –
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